Sellas Life Sciences Group Inc. (SLS) Advances Cancer Pipeline with $31M Funding and Upcoming R&D Showcase

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the top long-term biotechnology stocks to buy. On October 27, SELLAS Life Sciences (NASDAQ:SLS) announced the immediate exercise of warrants for 22.4 million shares. The company raised $31 million in gross proceeds from the offering.

Investors who exercised the warrants, issued in March and August of last year, are poised to receive new registered warrants to purchase up to 22.4 million shares at $2 per share. The new warrants will be exercisable immediately and will expire five years from issuance.

The offering comes as the company plans to host a virtual R&D Day on Wednesday, October 29, 2025, featuring opinion leaders and management to discuss an acute myeloid leukemia treatment. The company is developing its lead product candidate, GPS, in addition to SLS009, a CDK9 inhibitor for acute myeloid leukemia. Preliminary results indicate that CK9 inhibition with SLS009 could play a role in the treatment of T-cell prolymphocytic leukemia (T-PLL).

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is a biotechnology company that develops novel cancer therapies. Its lead candidate is galinpepimut-S (GPS), an immunotherapy targeting the WT1 protein for various cancers, and SLS009, a CDK9 inhibitor for certain types of leukemia.

While we acknowledge the potential of SLS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Billionaire Steve Cohen’s 10 Small-Cap Stock Picks with Huge Upside Potential and Top 9 Credit Services Stocks to Buy as the US Cuts Interest Rates.

Disclosure: None. This article is originally published at Insider Monkey.